Call for Abstract

28th European Nephrology Conference, will be organized around the theme “Innovations in Dialysis Technology: Shaping the Future of Renal Replacement Therapy”

EURO NEPHROLOGY 2024 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in EURO NEPHROLOGY 2024

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

CRISPR and gene editing have emerged as revolutionary tools in nephrology, offering promising avenues for precision medicine. In this rapidly evolving field, researchers are exploring how genetic manipulation can address various renal disorders with unparalleled precision. From targeting genetic mutations underlying inherited kidney diseases to potentially engineering immune cells for transplant tolerance, CRISPR technology holds immense therapeutic potential. One promising application is in polycystic kidney disease (PKD), where CRISPR enables targeted correction of disease-causing mutations. Additionally, gene editing may facilitate personalized treatments for kidney cancer by modifying genetic pathways driving tumor growth. Furthermore, CRISPR-based approaches hold promise in addressing the shortage of viable donor organs through xenotransplantation, where pig kidneys are modified for human compatibility. However, ethical considerations and off-target effects remain significant challenges. Despite this, ongoing research in CRISPR and gene editing within nephrology underscores a transformative shift towards tailored, precision therapies, offering hope for improved outcomes and quality of life for patients with kidney disorders.

Artificial Intelligence (AI) is revolutionizing renal diagnostics, promising enhanced accuracy and efficiency in identifying and managing kidney-related conditions. Through machine learning algorithms, AI analyzes vast datasets of patient information, laboratory results, and medical imaging to swiftly detect subtle patterns indicative of renal diseases. In renal diagnostics, AI-powered systems can streamline the interpretation of complex imaging modalities like ultrasound, CT scans, and MRI, assisting clinicians in early detection of kidney abnormalities such as tumors, cysts, or structural anomalies. Moreover, AI algorithms can analyze urine and blood biomarkers to predict the risk of kidney disease progression, enabling proactive interventions to mitigate adverse outcomes. By automating routine tasks and providing real-time decision support, AI augments the diagnostic capabilities of healthcare professionals, leading to quicker diagnoses and personalized treatment plans. However, challenges such as data privacy, algorithm bias, and regulatory compliance must be addressed to ensure the ethical and equitable implementation of AI in renal diagnostics. Nonetheless, the integration of AI holds promise in advancing renal care, improving patient outcomes, and optimizing healthcare resource utilization.

Nanotechnology offers a promising frontier in kidney therapeutics, harnessing the power of small-scale solutions to make a big impact on renal health. With their unique properties, nanomaterials enable targeted drug delivery, enhanced imaging, and precise manipulation of biological processes within the kidneys. In drug delivery, nanoparticles can encapsulate therapeutic agents, protecting them from degradation and delivering them directly to affected tissues. This targeted approach minimizes systemic side effects and improves drug efficacy in treating conditions such as kidney inflammation, fibrosis, and renal cell carcinoma. Moreover, nanotechnology enables the development of advanced imaging probes that enhance the visualization of renal structures and functions at the molecular level. This facilitates early detection and monitoring of kidney diseases, guiding clinicians in optimizing treatment strategies and improving patient outcomes. While challenges such as biocompatibility and safety need to be addressed, the integration of nanotechnology in kidney therapeutics holds immense potential to revolutionize renal care, offering innovative solutions for the management of diverse kidney disorders.

Immunotherapy represents a promising frontier in the management of glomerular diseases, offering a targeted approach to modulate the immune system's response and alleviate renal inflammation and damage. Glomerular diseases, encompassing a spectrum of conditions like glomerulonephritis and lupus nephritis, often involve dysregulated immune responses leading to kidney injury. Immunotherapeutic strategies aim to restore immune balance by targeting specific components of the immune system. This may involve monoclonal antibodies that block inflammatory cytokines or immune cells responsible for renal damage, thereby reducing inflammation and preserving kidney function. Additionally, therapies such as rituximab, which selectively deplete B cells, have shown efficacy in certain glomerular diseases characterized by abnormal antibody production. While immunotherapy holds promise in improving outcomes for patients with glomerular diseases, challenges such as identifying optimal treatment regimens and managing potential side effects remain. Nevertheless, ongoing research and clinical trials in immunomodulation offer hope for more effective and personalized approaches to tackling these complex renal conditions, ultimately aiming to improve patient prognosis and quality of life.

Digital biomarkers are transforming nephrology by leveraging wearable technology and remote monitoring to provide real-time insights into renal health. These innovative tools enable continuous tracking of key physiological parameters, allowing for early detection of changes indicative of kidney dysfunction or disease progression. Wearable devices equipped with sensors can monitor vital signs such as blood pressure, heart rate, and fluid balance, providing clinicians with valuable data to assess renal function and manage conditions like hypertension and fluid overload. Moreover, advanced algorithms analyze data patterns to generate personalized digital biomarkers, offering predictive analytics and risk stratification for renal complications. Remote monitoring platforms facilitate remote consultations and enable patients to actively participate in their care, fostering self-management and early intervention strategies. By enhancing proactive monitoring and timely intervention, digital biomarkers have the potential to improve outcomes, reduce hospitalizations, and optimize resource utilization in nephrology care. However, addressing privacy concerns and ensuring data accuracy are essential for the widespread adoption of these transformative technologies in renal healthcare.

Renal organoids have emerged as powerful tools in nephrology, offering a sophisticated platform to model kidney diseases and accelerate drug discovery efforts. These miniature, three-dimensional structures, derived from stem cells or patient-specific induced pluripotent stem cells (iPSCs), mimic the structural and functional complexity of the human kidney, providing a physiologically relevant model for studying renal development, physiology, and pathology. In drug discovery, renal organoids enable high-throughput screening of potential therapeutic compounds, offering a more predictive model compared to traditional two-dimensional cell cultures. Researchers can assess drug efficacy, toxicity, and mechanisms of action in a more physiologically relevant context, facilitating the identification of novel treatments for kidney diseases such as polycystic kidney disease, nephrotic syndrome, and diabetic nephropathy. Moreover, patient-derived organoids allow for personalized medicine approaches, wherein drugs can be tested on organoids generated from individuals with specific genetic mutations or disease phenotypes, enabling tailored treatment strategies. While challenges such as reproducibility and scalability persist, renal organoids hold immense promise in advancing our understanding of kidney diseases and expediting the development of novel therapies to improve patient outcomes in nephrology.

Advanced imaging techniques are revolutionizing nephrology by providing unparalleled insights into renal anatomy, function, and pathology. Among these techniques, 3D mapping and functional assessments stand out for their ability to offer comprehensive views of the kidneys' structure and physiology. 3D mapping allows clinicians to visualize the intricate architecture of renal tissues in three dimensions, enabling precise localization of abnormalities such as tumors, cysts, or renal artery stenosis. This enhances preoperative planning and facilitates targeted interventions, leading to improved patient outcomes. Functional assessments complement structural imaging by evaluating renal perfusion, filtration, and tubular function. Techniques such as dynamic contrast-enhanced MRI, renal scintigraphy, and positron emission tomography provide quantitative measures of renal function and hemodynamics, aiding in the diagnosis and monitoring of conditions like renal artery stenosis, acute kidney injury, and renal transplantation. By combining advanced structural and functional imaging modalities, nephrologists can obtain a comprehensive understanding of renal health, guiding treatment decisions and optimizing patient care in nephrology practice.

Kidney-on-a-chip technology represents a groundbreaking advancement in nephrology research, offering a sophisticated platform to mimic the complex physiological conditions of the human kidney in vitro. These microfluidic devices contain cultured kidney cells arranged in a precise architecture that replicates the cellular composition and function of renal tissue. By recreating the dynamic microenvironment of the kidney, including fluid flow, shear stress, and cellular interactions, kidney-on-a-chip models provide researchers with a powerful tool to study renal physiology, disease mechanisms, and drug responses with unprecedented accuracy and relevance. These innovative systems enable the investigation of various aspects of kidney function, including filtration, reabsorption, secretion, and transport, facilitating the exploration of renal disorders such as acute kidney injury, diabetic nephropathy, and drug-induced nephrotoxicity. Moreover, kidney-on-a-chip technology allows for high-throughput screening of potential therapeutic compounds, accelerating drug discovery and personalized medicine approaches in nephrology. As our understanding of renal biology continues to evolve, kidney-on-a-chip technology holds immense promise in advancing nephrology research, ultimately leading to improved diagnostics, treatments, and outcomes for patients with kidney diseases.

Personalized nutrition is gaining traction in nephrology as a tailored approach to optimizing dietary habits for renal health. Given the intricate interplay between diet and kidney function, individualized nutrition plans can play a pivotal role in managing various renal conditions and preventing disease progression. For individuals with chronic kidney disease (CKD), personalized nutrition involves careful monitoring of protein, phosphorus, potassium, sodium, and fluid intake to mitigate metabolic imbalances and minimize renal workload. Moreover, dietary modifications may be recommended based on factors such as disease stage, comorbidities, and medication regimens. Innovative tools such as dietary tracking apps and telehealth consultations enable healthcare providers to gather comprehensive data on patients' dietary habits and provide tailored recommendations accordingly. Additionally, genetic and metabolic profiling may inform personalized nutrition strategies by identifying individuals' unique nutrient requirements and metabolic responses. By emphasizing nutrient balance, portion control, and dietary diversity, personalized nutrition empowers patients to take an active role in managing their renal health and may complement traditional medical interventions to optimize outcomes and improve quality of life for individuals with kidney diseases.

Renal regenerative medicine represents a promising frontier in nephrology, harnessing the potential of stem cells and tissue engineering to restore damaged kidney tissue and function. Stem cell therapy offers a novel approach to replenishing lost or dysfunctional renal cells, promoting tissue repair, and improving kidney function. Mesenchymal stem cells (MSCs), derived from various sources such as bone marrow, adipose tissue, or umbilical cord blood, have shown therapeutic potential in preclinical and clinical studies for treating acute kidney injury and chronic kidney disease. These multipotent cells exert anti-inflammatory, immunomodulatory, and regenerative effects, facilitating tissue repair and regeneration. Moreover, tissue engineering approaches aim to develop bioengineered renal constructs that mimic the structural and functional complexity of native kidney tissue. These constructs, composed of biomaterial scaffolds and renal cells, hold promise for transplantation, drug testing, and disease modeling applications. While challenges such as immune rejection and tumorigenicity need to be addressed, renal regenerative medicine offers exciting opportunities to revolutionize nephrology by providing innovative treatments for kidney diseases and advancing regenerative therapies to enhance patient outcomes and quality of life.

Metabolomics has emerged as a powerful tool in nephrology, enabling researchers to unravel intricate metabolic pathways underlying various renal diseases and providing insights into disease mechanisms, biomarker discovery, and therapeutic targets. By comprehensively profiling small molecule metabolites present in biological samples like urine, blood, and tissue, metabolomics offers a holistic view of metabolic dysregulation associated with kidney dysfunction. In chronic kidney disease (CKD), metabolomics has identified metabolic signatures associated with disease progression, renal fibrosis, and complications such as cardiovascular disease and mineral bone disorders. Furthermore, metabolomic profiling facilitates the identification of novel biomarkers for early detection, risk stratification, and monitoring of kidney diseases. Moreover, metabolomics-guided interventions aim to modulate metabolic pathways implicated in renal pathology through dietary interventions, pharmacological agents, and lifestyle modifications, paving the way for personalized medicine approaches in nephrology. As our understanding of renal metabolism continues to evolve, metabolomics holds immense promise in advancing nephrology research, ultimately leading to improved diagnostics, treatments, and outcomes for patients with kidney diseases.

Blockchain technology is revolutionizing nephrology by enhancing the security, privacy, and transparency of health records. With its decentralized and tamper-resistant nature, blockchain ensures the integrity and confidentiality of sensitive patient data, safeguarding against unauthorized access and cyber threats. In nephrology, where patient information is critical for diagnosis, treatment, and ongoing care, blockchain offers a secure platform for storing and sharing electronic health records (EHRs). Patients have greater control over their medical data, granting permission for healthcare providers to access specific information while maintaining privacy rights. Moreover, blockchain facilitates seamless interoperability among disparate healthcare systems, enabling efficient exchange of medical records and fostering collaboration among healthcare providers involved in a patient's renal care. By providing an immutable and auditable record of health information, blockchain technology enhances trust and accountability in the healthcare ecosystem, ultimately improving data accuracy, patient outcomes, and the overall quality of nephrology care. As blockchain continues to evolve, its integration holds promise in addressing the challenges of data management and security in renal healthcare.

Extracellular vesicles (EVs) are emerging as key players in renal communication, offering insights into intercellular signaling and paving the way for novel therapeutic approaches in nephrology. These small membrane-bound vesicles, secreted by various renal cell types, contain a cargo of proteins, lipids, nucleic acids, and metabolites that reflect the physiological or pathological state of the kidney. In renal physiology, EVs facilitate cell-to-cell communication and regulate processes such as inflammation, immune response, and tissue repair. However, in renal diseases, EVs may carry disease-specific biomarkers and contribute to disease progression by promoting fibrosis, inflammation, and endothelial dysfunction. Exploiting the diagnostic and therapeutic potential of EVs holds promise in nephrology. EVs derived from stem cells, for instance, exhibit regenerative and immunomodulatory properties, offering potential therapeutic benefits for acute kidney injury, chronic kidney disease, and renal transplantation. Furthermore, EV-based therapies, such as engineered EVs loaded with therapeutic cargo, show promise in delivering targeted therapies to the kidneys, offering a novel approach to treat renal disorders effectively and improve patient outcomes.

Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, is revolutionizing renal care by enabling personalized treatment strategies tailored to each patient's unique genetic profile. Genetic variations can significantly impact drug metabolism, efficacy, and adverse effects, particularly in renal diseases where drug dosing and response are critical. By identifying genetic variants associated with drug metabolism enzymes, transporters, and drug targets, pharmacogenomics guides clinicians in selecting the most appropriate medications and optimizing dosages for individual patients. For example, genetic testing can identify individuals at risk of adverse drug reactions or those who may require dose adjustments to achieve therapeutic efficacy while minimizing toxicity. In nephrology, pharmacogenomics holds promise in improving outcomes and safety in areas such as immunosuppressive therapy post-transplantation, management of chronic kidney disease, and treatment of comorbid conditions like hypertension and diabetes. By integrating pharmacogenomic data into clinical decision-making, nephrologists can customize treatments, enhance therapeutic outcomes, and mitigate adverse drug reactions, ultimately improving patient care and quality of life in renal medicine.

In nephrology care, patient-reported outcomes (PROs) and shared decision-making (SDM) play pivotal roles in fostering patient-centered approaches and optimizing treatment plans. PROs, which encompass patients' perspectives on their health status, symptoms, and quality of life, provide valuable insights into the impact of kidney diseases on patients' daily lives. By incorporating PROs into clinical assessments, nephrologists gain a more comprehensive understanding of patients' needs, preferences, and treatment goals, allowing for tailored interventions that address individual priorities and concerns. Moreover, PROs facilitate open communication between patients and healthcare providers, fostering trust, engagement, and shared decision-making. SDM involves collaborative discussions between patients and clinicians to explore treatment options, discuss risks and benefits, and arrive at mutually agreed-upon decisions. By involving patients in the decision-making process, SDM promotes autonomy, adherence, and satisfaction with treatment plans. Incorporating PROs and SDM into nephrology care enhances patient outcomes, promotes patient-centered care, and empowers individuals to actively participate in managing their kidney health, ultimately leading to improved quality of life and treatment adherence in renal medicine.

Smart dialysis devices represent a transformative innovation in nephrology, offering enhanced convenience, flexibility, and autonomy for patients undergoing renal replacement therapy. These advanced devices integrate cutting-edge technologies such as connectivity, sensors, and automation to streamline dialysis procedures and improve patient outcomes. One key advantage of smart dialysis devices is their suitability for home-based therapies, enabling patients to undergo dialysis in the comfort of their own environment. By eliminating the need for frequent clinic visits and providing real-time monitoring capabilities, these devices empower patients to take greater control of their treatment schedules and optimize their dialysis experience. Moreover, smart dialysis devices incorporate intelligent algorithms that adjust treatment parameters based on individual patient needs and physiological responses, optimizing dialysis efficiency and minimizing the risk of complications. By offering personalized, precision therapies, these devices aim to improve treatment adherence, quality of life, and clinical outcomes for individuals with kidney failure. As smart dialysis technology continues to evolve, it holds immense promise in revolutionizing renal care delivery, enabling more accessible, convenient, and effective dialysis treatments for patients worldwide.

Renal health in aging populations presents unique challenges and considerations, driving the need for ongoing updates and advancements in the field of geriatric nephrology. With aging, physiological changes such as decreased renal function, altered drug metabolism, and increased comorbidities pose significant implications for kidney health and management. Geriatric nephrology focuses on addressing these complexities through comprehensive assessment, tailored interventions, and multidisciplinary care approaches. Clinicians must consider factors such as frailty, cognitive impairment, polypharmacy, and functional status when managing kidney diseases in older adults. Recent updates in geriatric nephrology emphasize personalized approaches to renal care, incorporating patient-centered goals, shared decision-making, and proactive management of comorbid conditions. Additionally, ongoing research explores novel strategies for early detection, prevention, and treatment of kidney diseases in older populations, aiming to improve outcomes, enhance quality of life, and promote healthy aging for older adults with renal conditions.